Oral Cancer Therapeutics Market 2024-2028: Size and Side effects of chemotherapeutics; growth driven by the Product, Some of key Companies Positioned Strategically

The oral cancer therapeutics market size by Product (Targeted therapy and Chemotherapy) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1615.4 million. The market is expected to grow at a CAGR of   10.03% between 2024 and 2028.

• In the realm of oral cancer therapeutics, the advancements in chemotherapeutic treatments have led to enhanced efficacy and increased survival rates. However, these improvements come with challenges, as patients often grapple with debilitating side effects. Among these, delayed acute chemotherapy-induced nausea and vomiting pose significant difficulties. Furthermore, gastrointestinal side effects are the second most common, causing local ulceration, pain, malabsorption, anemia, and fatigue. Notable chemotherapeutics, such as Carboplatin, 5-fluorouracil, paclitaxel (TAXOL), docetaxel (TAXOTERE), and hydroxyurea, are employed in the treatment of oral cancer, necessitating effective management of these side effects to ensure optimal patient care and well-being.
• The oral cancer therapeutics market represents a significant business opportunity due to the rising prevalence of oral cancer worldwide. Key players in this market are focusing on developing innovative treatments to address the unmet medical needs of patients. Advanced technologies, such as targeted therapies and immunotherapies, are gaining traction in the market. The market is expected to grow at a robust rate, driven by increasing awareness, improving healthcare infrastructure, and rising disposable income in emerging economies.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Amneal Pharmaceuticals Inc.
• AstraZeneca Plc
• Bristol Myers Squibb Co.
• Cipla Inc.
• Eli Lilly and Co.
• Endo International Plc
• F. Hoffmann La Roche Ltd.
• Fresenius SE and Co. KGaA
• GlaxoSmithKline Plc
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Merck and Co. Inc.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/